SLNO Profile
Soleno Therapeutics, Inc., headquartered in Redwood City, California, is a prominent clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for the treatment of rare diseases. Established in 1999 and formerly known as Capnia, Inc., the company underwent a strategic rebranding to Soleno Therapeutics, Inc. in May 2017, reflecting its focused mission on addressing critical unmet medical needs through groundbreaking research and development initiatives.
At the forefront of Soleno Therapeutics' pipeline is Diazoxide Choline Controlled-Release (DCCR), a pioneering once-daily oral tablet designed specifically for the treatment of Prader-Willi Syndrome (PWS). PWS is a complex genetic disorder characterized by hyperphagia, a chronic feeling of insatiable hunger leading to severe obesity and other metabolic disturbances. Soleno Therapeutics is currently advancing DCCR through an extensive Phase III clinical development program, aiming to provide a transformative therapeutic option for individuals affected by this challenging condition.
In addition to its commitment to PWS, Soleno Therapeutics explores potential applications of DCCR across various other rare diseases and metabolic disorders. The company's innovative approach leverages its expertise in drug development and regulatory affairs to accelerate the translation of scientific discoveries into viable treatment options. Soleno Therapeutics collaborates closely with healthcare professionals, patient advocacy groups, and regulatory authorities to navigate the complex landscape of clinical research and drug approval processes.
Beyond its therapeutic advancements, Soleno Therapeutics remains dedicated to enhancing its corporate infrastructure and expanding its global footprint. The company engages in strategic partnerships and alliances to bolster its capabilities in research, manufacturing, and commercialization, ensuring that its pipeline candidates reach patients efficiently and effectively. With a steadfast commitment to scientific rigor and patient-centric innovation, Soleno Therapeutics is poised to make significant contributions to improving the lives of individuals affected by rare diseases worldwide.
|
